1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Synthetic	_	_	JJ	_	_	_	_	_
2	lethality	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	immense	_	_	JJ	_	_	_	_	_
5	potential	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	cancer	_	_	NN	_	_	_	_	_
8	therapeutics	_	_	NNS	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Where	_	_	WRB	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	driver	_	_	NN	_	_	_	_	_
4	genes	_	_	NNS	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	oncogenes	_	_	NNS	_	_	_	_	_
7	cannot	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	targeted	_	_	VBN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	synthetic	_	_	JJ	_	_	_	_	_
12	lethal	_	_	JJ	_	_	_	_	_
13	interactors	_	_	NNS	_	_	_	_	_
14	can	_	_	MD	_	_	_	_	_
15	potentially	_	_	RB	_	_	_	_	_
16	serve	_	_	VB	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	targets	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	presence	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	mutations	_	_	NNS	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	driver	_	_	NN	_	_	_	_	_
28	genes	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	as	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	mutant	_	_	JJ	_	_	_	_	_
33	tumor	_	_	NN	_	_	_	_	_
34	cells	_	_	NNS	_	_	_	_	_
35	are	_	_	VBP	_	_	_	_	_
36	dependent	_	_	VBN	_	_	_	_	_
37	upon	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	synthetic	_	_	JJ	_	_	_	_	_
40	lethal	_	_	JJ	_	_	_	_	_
41	interactors	_	_	NNS	_	_	_	_	_
42	for	_	_	IN	_	_	_	_	_
43	their	_	_	PRP$	_	_	_	_	_
44	survival	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	advances	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	RNAi	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	CRISPR	_	_	NNP	_	_	_	_	_
7	technologies	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	enabled	_	_	VBN	_	_	_	_	_
10	large-scale	_	_	JJ	_	_	_	_	_
11	synthetic	_	_	JJ	_	_	_	_	_
12	lethality	_	_	NN	_	_	_	_	_
13	screens	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	individual	_	_	JJ	_	_	_	_	_
16	genes	_	_	NNS	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	performed	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	human	_	_	JJ	_	_	_	_	_
22	cell	_	_	NN	_	_	_	_	_
23	lines	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	genetic	_	_	JJ	_	_	_	_	_
3	dependency	_	_	NN	_	_	_	_	_
4	map	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	DepMap	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	project	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	dedicated	_	_	VBN	_	_	_	_	_
11	towards	_	_	IN	_	_	_	_	_
12	finding	_	_	VBG	_	_	_	_	_
13	genetic	_	_	JJ	_	_	_	_	_
14	dependencies	_	_	NNS	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	published	_	_	VBN	_	_	_	_	_
18	shRNA/CRISPR	_	_	NN	_	_	_	_	_
19	or	_	_	CC	_	_	_	_	_
20	drug	_	_	NN	_	_	_	_	_
21	screening	_	_	NN	_	_	_	_	_
22	data	_	_	NNS	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	cancer	_	_	NN	_	_	_	_	_
25	cell	_	_	NN	_	_	_	_	_
26	lines	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	identifying	_	_	VBG	_	_	_	_	_
3	genetic	_	_	JJ	_	_	_	_	_
4	dependencies	_	_	NNS	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	essentiality	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	context	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	specific	_	_	JJ	_	_	_	_	_
12	genetic	_	_	JJ	_	_	_	_	_
13	alterations	_	_	NNS	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	important	_	_	JJ	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	screening	_	_	VBG	_	_	_	_	_
18	potential	_	_	JJ	_	_	_	_	_
19	targets	_	_	NNS	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	cancer	_	_	NN	_	_	_	_	_
22	therapy	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	identification	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	clinically	_	_	RB	_	_	_	_	_
27	relevant	_	_	JJ	_	_	_	_	_
28	synthetic	_	_	JJ	_	_	_	_	_
29	lethal	_	_	JJ	_	_	_	_	_
30	pairs	_	_	NNS	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	cancers	_	_	NNS	_	_	_	_	_
33	has	_	_	VBZ	_	_	_	_	_
34	been	_	_	VBN	_	_	_	_	_
35	a	_	_	DT	_	_	_	_	_
36	challenge	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	work	_	_	NN	_	_	_	_	_
4	tried	_	_	VBD	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	address	_	_	VB	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	limitation	_	_	NN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	silico	_	_	JJ	_	_	_	_	_
13	analysis	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	clinical	_	_	JJ	_	_	_	_	_
16	relevance	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	SL	_	_	NNP	_	_	_	_	_
20	interactions	_	_	NNS	_	_	_	_	_
21	identified	_	_	VBN	_	_	_	_	_
22	from	_	_	IN	_	_	_	_	_
23	in	_	_	FW	_	_	_	_	_
24	vitro	_	_	FW	_	_	_	_	_
25	SL	_	_	NN	_	_	_	_	_
26	screens	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	reported	_	_	VBD	_	_	_	_	_
29	that	_	_	IN	_	_	_	_	_
30	only	_	_	RB	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	fraction	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	these	_	_	DT	_	_	_	_	_
35	SL	_	_	NN	_	_	_	_	_
36	interactions	_	_	NNS	_	_	_	_	_
37	hold	_	_	VBP	_	_	_	_	_
38	up	_	_	RP	_	_	_	_	_
39	to	_	_	TO	_	_	_	_	_
40	be	_	_	VB	_	_	_	_	_
41	clinically	_	_	RB	_	_	_	_	_
42	significant	_	_	JJ	_	_	_	_	_
43	when	_	_	WRB	_	_	_	_	_
44	tested	_	_	VBN	_	_	_	_	_
45	on	_	_	IN	_	_	_	_	_
46	TCGA	_	_	NNP	_	_	_	_	_
47	tumor	_	_	NN	_	_	_	_	_
48	data	_	_	NNS	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	vitro	_	_	NN	_	_	_	_	_
6	screens	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	costly	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	finding	_	_	VBG	_	_	_	_	_
11	synthetic	_	_	JJ	_	_	_	_	_
12	lethal	_	_	JJ	_	_	_	_	_
13	interactors	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	many	_	_	JJ	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	genes	_	_	NNS	_	_	_	_	_
18	remain	_	_	VBP	_	_	_	_	_
19	challenging	_	_	JJ	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	SL-BioDP	_	_	NNP	_	_	_	_	_
2	addresses	_	_	VBZ	_	_	_	_	_
3	such	_	_	JJ	_	_	_	_	_
4	problems	_	_	NNS	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	using	_	_	VBG	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	computational	_	_	JJ	_	_	_	_	_
9	method	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	leverages	_	_	VBZ	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	available	_	_	JJ	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	genetic	_	_	JJ	_	_	_	_	_
16	data	_	_	NN	_	_	_	_	_
17	resources	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	predict	_	_	VB	_	_	_	_	_
20	synthetic	_	_	JJ	_	_	_	_	_
21	lethal	_	_	JJ	_	_	_	_	_
22	partners	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	all	_	_	DT	_	_	_	_	_
25	cancer	_	_	NN	_	_	_	_	_
26	susceptibility	_	_	NN	_	_	_	_	_
27	genes	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	assesses	_	_	VBZ	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	clinical	_	_	JJ	_	_	_	_	_
32	relevance	_	_	NN	_	_	_	_	_
33	from	_	_	IN	_	_	_	_	_
34	matched	_	_	VBN	_	_	_	_	_
35	clinical	_	_	JJ	_	_	_	_	_
36	data	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	computational	_	_	JJ	_	_	_	_	_
3	predictions	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	SL	_	_	NN	_	_	_	_	_
6	interactions	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	subjected	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	extensive	_	_	JJ	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	silico	_	_	JJ	_	_	_	_	_
13	validation	_	_	NN	_	_	_	_	_
14	using	_	_	VBG	_	_	_	_	_
15	either	_	_	CC	_	_	_	_	_
16	published	_	_	VBN	_	_	_	_	_
17	literature	_	_	NN	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	shRNA	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	drug	_	_	NN	_	_	_	_	_
22	screening	_	_	NN	_	_	_	_	_
23	data	_	_	NNS	_	_	_	_	_
24	from	_	_	IN	_	_	_	_	_
25	cancer	_	_	NN	_	_	_	_	_
26	cell	_	_	NN	_	_	_	_	_
27	lines	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	SL-BioDP	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	comprehensive	_	_	JJ	_	_	_	_	_
5	resource	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	query	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	visualization	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	cancer-specific	_	_	JJ	_	_	_	_	_
13	synthetic	_	_	JJ	_	_	_	_	_
14	lethality	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	potential	_	_	JJ	_	_	_	_	_
17	drug	_	_	NN	_	_	_	_	_
18	targets	_	_	NNS	_	_	_	_	_
19	based	_	_	VBN	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	concept	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	synthetic	_	_	JJ	_	_	_	_	_
25	lethality	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	utility	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	web	_	_	NN	_	_	_	_	_
6	tool	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	it	_	_	PRP	_	_	_	_	_
10	enables	_	_	VBZ	_	_	_	_	_
11	multilevel	_	_	JJ	_	_	_	_	_
12	querying	_	_	NN	_	_	_	_	_
13	based	_	_	VBN	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	cancer	_	_	NN	_	_	_	_	_
16	genes	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	tissues	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	or	_	_	CC	_	_	_	_	_
21	drugs	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	interest	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	other	_	_	JJ	_	_	_	_	_
6	database	_	_	NN	_	_	_	_	_
7	resources	_	_	NNS	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	synthetic	_	_	JJ	_	_	_	_	_
10	lethality	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	SL-BioDP	_	_	NNP	_	_	_	_	_
13	enables	_	_	VBZ	_	_	_	_	_
14	assessment	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	clinical	_	_	JJ	_	_	_	_	_
18	relevance	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	targeting	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	SL	_	_	NN	_	_	_	_	_
23	interactor	_	_	NN	_	_	_	_	_
24	gene	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	presence	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	mutation	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	primary	_	_	JJ	_	_	_	_	_
33	gene	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	prediction	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	drug	_	_	NN	_	_	_	_	_
5	response	_	_	NN	_	_	_	_	_
6	depending	_	_	VBG	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	presence	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	mutations	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	primary	_	_	JJ	_	_	_	_	_
15	genes	_	_	NNS	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	another	_	_	DT	_	_	_	_	_
18	important	_	_	JJ	_	_	_	_	_
19	feature	_	_	NN	_	_	_	_	_
20	added	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	SL-BioDP	_	_	NNP	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	analysis	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	published	_	_	VBN	_	_	_	_	_
5	drug	_	_	NN	_	_	_	_	_
6	screening	_	_	NN	_	_	_	_	_
7	data	_	_	NNS	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	gene	_	_	NN	_	_	_	_	_
10	mutation	_	_	NN	_	_	_	_	_
11	data	_	_	NNS	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	matched	_	_	VBN	_	_	_	_	_
14	cancer	_	_	NN	_	_	_	_	_
15	cell	_	_	NN	_	_	_	_	_
16	lines	_	_	NNS	_	_	_	_	_
17	identified	_	_	VBN	_	_	_	_	_
18	known	_	_	VBN	_	_	_	_	_
19	synthetic	_	_	JJ	_	_	_	_	_
20	lethality-based	_	_	JJ	_	_	_	_	_
21	drug	_	_	NN	_	_	_	_	_
22	targets	_	_	NNS	_	_	_	_	_
23	like	_	_	IN	_	_	_	_	_
24	sensitivity	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	drug	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	olaparib	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	PARP	_	_	NN	_	_	_	_	_
32	inhibitor	_	_	NN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	presence	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	mutation	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	BRCA1	_	_	NN	_	_	_	_	_
42	gene	_	_	NN	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	general	_	_	JJ	_	_	_	_	_
47	the	_	_	DT	_	_	_	_	_
48	homologous	_	_	JJ	_	_	_	_	_
49	recombination	_	_	NN	_	_	_	_	_
50	repair	_	_	NN	_	_	_	_	_
51	pathway	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	analysis	_	_	NN	_	_	_	_	_
6	offers	_	_	VBZ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	look	_	_	VB	_	_	_	_	_
9	into	_	_	IN	_	_	_	_	_
10	new	_	_	JJ	_	_	_	_	_
11	potentially	_	_	RB	_	_	_	_	_
12	effective	_	_	JJ	_	_	_	_	_
13	gene	_	_	NN	_	_	_	_	_
14	mutation-based	_	_	JJ	_	_	_	_	_
15	drug	_	_	NN	_	_	_	_	_
16	therapies	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	extended	_	_	VBD	_	_	_	_	_
3	our	_	_	PRP$	_	_	_	_	_
4	analysis	_	_	NN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	infer	_	_	VB	_	_	_	_	_
7	potential	_	_	JJ	_	_	_	_	_
8	synergy	_	_	NN	_	_	_	_	_
9	between	_	_	IN	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	targeting	_	_	VBG	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	predicted	_	_	VBN	_	_	_	_	_
14	SL	_	_	NN	_	_	_	_	_
15	interactors	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	reasoned	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	if	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	presence	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	mutation	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	loss	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	function	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	primary	_	_	JJ	_	_	_	_	_
19	gene	_	_	NN	_	_	_	_	_
20	makes	_	_	VBZ	_	_	_	_	_
21	cancer	_	_	NN	_	_	_	_	_
22	cells	_	_	NNS	_	_	_	_	_
23	sensitive	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	certain	_	_	JJ	_	_	_	_	_
26	drugs	_	_	NNS	_	_	_	_	_
27	targeting	_	_	VBG	_	_	_	_	_
28	an	_	_	DT	_	_	_	_	_
29	SL	_	_	NN	_	_	_	_	_
30	interactor	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	then	_	_	RB	_	_	_	_	_
33	it	_	_	PRP	_	_	_	_	_
34	is	_	_	VBZ	_	_	_	_	_
35	highly	_	_	RB	_	_	_	_	_
36	likely	_	_	JJ	_	_	_	_	_
37	that	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	drugs	_	_	NNS	_	_	_	_	_
40	targeting	_	_	VBG	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	primary	_	_	JJ	_	_	_	_	_
43	gene	_	_	NN	_	_	_	_	_
44	will	_	_	MD	_	_	_	_	_
45	also	_	_	RB	_	_	_	_	_
46	make	_	_	VB	_	_	_	_	_
47	the	_	_	DT	_	_	_	_	_
48	cancer	_	_	NN	_	_	_	_	_
49	cells	_	_	NNS	_	_	_	_	_
50	sensitive	_	_	JJ	_	_	_	_	_
51	to	_	_	TO	_	_	_	_	_
52	those	_	_	DT	_	_	_	_	_
53	drugs	_	_	NNS	_	_	_	_	_
54	targeting	_	_	VBG	_	_	_	_	_
55	the	_	_	DT	_	_	_	_	_
56	SL	_	_	NNP	_	_	_	_	_
57	interactor	_	_	NN	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	inferred	_	_	JJ	_	_	_	_	_
3	drug	_	_	NN	_	_	_	_	_
4	synergies	_	_	NNS	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	searched	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	SL-BioDP	_	_	NNP	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	each	_	_	DT	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	18	_	_	CD	_	_	_	_	_
15	tumor	_	_	NN	_	_	_	_	_
16	histologies	_	_	NNS	_	_	_	_	_
17	included	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	SL-BioDP	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	support	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	predictions	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	synergistic	_	_	JJ	_	_	_	_	_
8	drugs	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	cancers	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	we	_	_	PRP	_	_	_	_	_
13	collected	_	_	VBD	_	_	_	_	_
14	literature	_	_	NN	_	_	_	_	_
15	references	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	reports	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	ongoing	_	_	JJ	_	_	_	_	_
20	clinical	_	_	JJ	_	_	_	_	_
21	trials	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	included	_	_	VBN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	Supplementary	_	_	NNP	_	_	_	_	_
28	Table	_	_	NNP	_	_	_	_	_
29	S3	_	_	NNP	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Combined	_	_	VBN	_	_	_	_	_
2	together	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	SL-BioDP	_	_	NNP	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	serve	_	_	VB	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	comprehensive	_	_	JJ	_	_	_	_	_
10	tool	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	exploring	_	_	VBG	_	_	_	_	_
14	potentially	_	_	RB	_	_	_	_	_
15	actionable	_	_	JJ	_	_	_	_	_
16	mutation-based	_	_	JJ	_	_	_	_	_
17	targeted	_	_	VBN	_	_	_	_	_
18	therapies	_	_	NNS	_	_	_	_	_
19	based	_	_	VBN	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	concept	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	synthetic	_	_	JJ	_	_	_	_	_
25	lethality	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	that	_	_	WDT	_	_	_	_	_
28	shows	_	_	VBZ	_	_	_	_	_
29	possible	_	_	JJ	_	_	_	_	_
30	clinical	_	_	JJ	_	_	_	_	_
31	relevance	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_

